

# REACX PHARMACEUTICALS AWARDED \$10.35 MILLION GRANT TO ADVANCE NALMEFENE IMPLANT FOR OPIOID RELAPSE PREVENTION

*Implant to use the Company's proprietary ProNeura™ drug delivery system*

SOUTH SAN FRANCISCO, CA, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- ReacX Pharmaceuticals, Inc. ("ReacX" or the "Company"), a company focused on developing and marketing pharmaceutical treatments for addictions, announced it has been awarded a three-year, \$10.35 million grant (the "Grant") from the National Institute on Drug Abuse ("NIDA"). The Grant is awarded under the National Institutes of Health ("NIH") HEAL Initiative ("The Helping to End Addiction Long-term Initiative") and is to support the clinical development of a six-month nalmefene implant using ReacX's proprietary ProNeura™ drug delivery system, which enables long-term, continuous medication release. The implant is being developed to prevent opioid addiction relapse after detoxification.

"This grant reflects NIDA's recognition of our ProNeura technology and its potential to address the ongoing opioid crisis," said Dr. Raj Patel, Chief Operating Officer of ReacX and Principal Investigator for the project. "We are committed to advancing long-term treatment options that improve patient outcomes and reduce relapse risks."

Following a comprehensive scientific and technical review, NIDA selected ReacX for funding to advance this program into the UH3 phase. The grant will cover clinical research and development, including two planned Phase 1/2 clinical studies. If successful, they will support Phase 3 clinical studies towards the filing of a New Drug Application (NDA) application with the U.S. Food and Drug Administration (FDA). ReacX owns full commercial rights to the product and its underlying intellectual property.

"Expanding access to long-term opioid addiction treatments is critical and is core to the purpose of ReacX," stated Dominic Leslie, President. "As we continue commercial efforts with Probuaphine®, our first FDA-approved product, we see tremendous potential for our nalmefene implant to serve as a vital new tool in addiction fighting treatments."

About ReacX Pharmaceuticals

ReacX Pharmaceuticals, Inc., headquartered in South San Francisco, CA, is a commercial-stage biopharmaceutical company developing therapeutics based on its proprietary ProNeura™ drug

delivery technology. The company's flagship product, Probuphine<sup>®</sup>, is the first FDA-approved long-acting formulation of buprenorphine designed for the maintenance treatment of opioid dependence. It provides continuous, six-month drug delivery following a single implant procedure, ensuring consistent therapeutic levels.

Beyond opioid addiction treatment, ProNeura<sup>™</sup> technology is being explored as a platform to develop treatments for other chronic conditions such as diabetes, psychosis, multiple sclerosis, and even weight loss where stable, long-term drug release can enhance patient care and outcomes.

For more information about ReacX Pharmaceuticals, visit [www.reacxpharma.com](http://www.reacxpharma.com).

### Forward Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Any forward-looking statement peaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

REACX PHARMACEUTICALS  
dleslie@reacxpharma.com  
rpatel@reacxpharma.com  
400 Oyster Point Blvd, #326, South San Francisco, CA 94080

Rajesh Patel  
ReacX Pharmaceuticals, Inc  
+1 650-438-5769

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/782917069>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.